To the Editor: An estimated 80% of congenital heart defects result from an interaction between susceptibilities in parental and fetal genomes and environmental exposures including maternal lifestyle factors (1). We and others have recently reported that women who have congenital heart defect-affected pregnancies have alterations in folate metabolism (2). This population-based case-control study was undertaken to determine whether these alterations are associated with specific cardiac phenotypes in their children. The study population, eligibility criteria, and methods have been previously published (2).
95% confidence intervals (CI) for the association between plasma biomarkers and cardiac phenotypes status were computed using logistic regression. For each biomarker, quartile cut-points were computed based on the distribution of biomarkers among control patients. Data analyses were performed using the SAS statistical package (version 9.1, SAS Institute, Cary, North Carolina). A total of 285 congenital heart defect cases and 157 control patients had plasma biomarkers measured. The participation rate was 91.5% for cases and 78.0% for control patients. The most prevalent congenital heart defect phenotype was septal heart defects (43.9%), followed by right-sided obstructive defects (19.3%), and left-sided obstructive defects (14.0%). Only 35 (12.3%) of the case children had conotruncal defects. There were 30 (10.5%) cases that had three or more of the above cardiac defects (complex).
The sample consisted primarily of Caucasian women; 63% of the cases were younger than age 30 years; and Ͻ40% reported regular multivitamin use. Nearly 48% of cases consumed alcohol. Smoking was more prevalent among cases than control patients (28.8% vs. 15.3% respectively, p ϭ 0.0016). There were no significant differences between cases and control patients in median dietary and total micronutrient intake from diet plus supplements, including methionine, folate, vitamin B6, and vitamin B12.
Plasma concentrations for homocysteine, methionine, and folate are summarized in Table 1 . After controlling for covariates, including maternal age, race, education, smoking, multivitamin supplement intake, alcohol consumption, lactation status, caffeine intake, energy-adjusted dietary folate intake, and the interval between the end of pregnancy and venipuncture, plasma homocysteine levels were significantly elevated in all phenotypes compared with control patients. Women who had children with septal, right-sided, and left-sided obstructive lesions had significantly lower methionine than control patients. Folate levels in women who had pregnancies affected by right-sided obstructive lesions were significantly lower than control patients. Table 2 shows adjusted odds ratios for the association between each biomarker and selected cardiac phenotypes. Among women who had homocysteine concentrations in the highest quartile, the odds of being a case were significantly greater than the odds of being a control. The ORs ranged from 3.69 (95% CI 2.10 to 6.49) for women with children with septal defects to 9.11 (95% CI 3.24 to 25.60) for those with a child with conotruncal defects. For those in the lowest quartile of methionine, the highest OR was observed for women who had a child affected by a left-sided obstructive lesion (OR 3.42; 95% CI 1.55 to 7.55). For women in the lowest quartile of plasma folate distribution, all odds ratios had corresponding 95% CIs that included one.
Our findings indicate that women who had children with congenital heart defects had higher plasma homocysteine concentrations than women without such a history. Among most congenital heart defects, folate intake from diet and supplements was similar between cases and control patients, as was mean plasma folate concentration. Following mandatory food fortification with folic acid, homocysteine may be a more salient marker of increased risk than folate intake or plasma folate concentrations. The mean plasma methionine concentrations were significantly different from control patients among women who had children affected by septal and obstructive defects, but not among those who had children with conotruncal or complex defects.
Important methodologic limitations of our study should be considered. Our intent was to compare plasma biomarker concentrations in women who had a specific congenital heart defectaffected pregnancy compared with control women. Because of limitations in sample sizes for some congenital heart defect phenotypes, we had limited statistical power to detect a difference in plasma biomarker concentration distributions across cardiac phenotypes. Cases had higher participation rates than control patients, and thus factors that determined participation rates may be differentially distributed between cases and control patients. Although plasma biomarkers were not measured at organogenesis, our findings support the hypothesis that imbalances in homocysteine metabolism exist in women with congenital heart defectaffected pregnancies. To the Editor: Adjunctive abciximab has been shown to reduce mortality in patients undergoing mechanical revascularization for ST-segment elevation myocardial infarction (STEMI) (1) . The goal of this study was to investigate, by the use of a metaregression analysis of randomized trials, whether the benefits in long-term mortality from abciximab administration correlated with the patient's risk profile. The literature was scanned by formal searches of electronic databases (MEDLINE, PubMed) and the scientific session abstracts in Circulation, the Journal of American College of Cardiology, and the European Heart Journal from January 1990 to December 2004. The following key words were used: randomized trial, myocardial infarction, reperfusion, primary angioplasty, facilitated angioplasty, stenting, glycoprotein IIb/IIIa inhibitors, abciximab. All data were extracted by two investigators. Data were managed according to the intention-to-treat principle.
The end point was mortality at 6 to 12 months of follow-up. Statistical analysis was performed using the Review Manager 4.27 freeware package (Cochrane Collaboration, Oxford, United Kingdom), the SPSS 11.5 statistical package (SPSS Inc., Chicago, Illinois), and SAS version 8.2 (SAS Institute Inc., Cary, North Carolina). Odds ratio (OR) and 95% confidence intervals (CIs) were used as summary statistics (1) .
A fixed-effect meta-regression analysis for the log-odds ratio on mortality (expressed as odds) of the control group was carried out by resorting to the Proc MIXED procedure of SAS version 8.2 (SAS Institute Inc.) according to the approach proposed by van Houwelingen et al. (2) . Results are reported as regression coefficients with associated 95% CI and two-sided p values. The estimated meta-regression line was plotted in graph together with the observed log-odds ratios.
A total of seven randomized trials with available follow-up data were analyzed (Table 1) , involving 3,918 patients (1,999 in the abciximab group and 1,919 in the placebo group). In almost all trials, abciximab was started after initial angiography. Abciximab was associated with a significant reduction in 6-to 12-month mortality (4.4% vs. 6.2%, OR [95% CI] ϭ 0.69 [0.52 to 0.92], p ϭ 0.01, p heterogeneity ϭ 0.15). Figure 1 shows the relationship between the patient's risk profile and the benefits from abciximab administration in terms of 6-to 12-month mortality (b ϭ Ϫ9.9 [Ϫ20.1 to 0.21], p ϭ 0.053).
The main finding of this meta-analysis is that the mortality benefits of adjunctive abciximab therapy to mechanical revascularization for ST-segment elevation myocardial infarction are related to the patient's risk profile.
The benefits in mortality may be the effects of abciximab in reducing distal embolization and improving myocardial perfusion, factors known to be determinants of long-term survival (3) .
It should be remarked that highly selected non-high-risk patients are commonly enrolled in randomized trials, whereas benefits in mortality have been shown mostly in trials enrolling high-risk patients. In fact, by using a meta-regression analysis, a direct correlation was found between the patient's risk profile and the benefits from abciximab administration in terms of long-term 
